Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

10.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

5.0K
Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
5.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

7.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

7.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Brain Network Connectivity Predicts Survival in Diffuse Midline Glioma.

Cancer discovery·2026
Same journal

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

Cancer discovery·2026
Same journal

CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.

Cancer discovery·2026
Same journal

CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma.

Cancer discovery·2026
Same journal

SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer.

Cancer discovery·2026
Same journal

Nonprofit Acquires Abandoned Leukemia Drug Supply.

Cancer discovery·2026

Related Experiment Video

Updated: Apr 30, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

5.7K

SAICAR binding activates PKM2 protein kinase activity

    Cancer Discovery
    |May 6, 2014
    PubMed
    Summary

    SAICAR activates PKM2 protein kinase, which is essential for cancer cell growth stimulated by EGF. This finding highlights a key mechanism in cancer proliferation.

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Cancer Research

    Background:

    • Epidermal Growth Factor (EGF) receptor signaling is a critical pathway in cancer progression.
    • Pyruvate Kinase M2 (PKM2) is a key enzyme implicated in cancer metabolism and proliferation.
    • SAICAR (Succinyladenosine monophosphate) is an intermediate in purine biosynthesis.

    Purpose of the Study:

    • To investigate the role of SAICAR in regulating PKM2 activity.
    • To determine if SAICAR-mediated PKM2 activation is required for EGF-induced cancer cell proliferation.

    Main Methods:

    • Western blotting to assess protein levels and phosphorylation.
    • Enzyme activity assays to measure PKM2 kinase activity.
    • Cell proliferation assays (e.g., MTT, BrdU incorporation) in cancer cell lines treated with EGF and SAICAR inhibitors.

    More Related Videos

    Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle
    10:05

    Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle

    Published on: March 5, 2019

    6.1K
    Assaying Protein Kinase Activity with Radiolabeled ATP
    08:05

    Assaying Protein Kinase Activity with Radiolabeled ATP

    Published on: May 26, 2017

    18.0K

    Related Experiment Videos

    Last Updated: Apr 30, 2026

    Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
    08:45

    Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

    Published on: July 17, 2020

    5.7K
    Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle
    10:05

    Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle

    Published on: March 5, 2019

    6.1K
    Assaying Protein Kinase Activity with Radiolabeled ATP
    08:05

    Assaying Protein Kinase Activity with Radiolabeled ATP

    Published on: May 26, 2017

    18.0K

    Main Results:

    • SAICAR directly enhances PKM2 protein kinase activity.
    • Inhibition of SAICAR or PKM2 activity abrogated EGF-stimulated cancer cell proliferation.
    • EGF stimulation led to increased intracellular SAICAR levels.

    Conclusions:

    • SAICAR-dependent activation of PKM2 kinase is a crucial step in the EGF signaling pathway driving cancer cell proliferation.
    • Targeting the SAICAR-PKM2 axis represents a potential therapeutic strategy for cancers driven by EGF signaling.